Literature DB >> 25937215

Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.

Toshihiro Nomura1, Yoshihiro Oyamada2, Herman B Fernandes1, Christine L Remmers1, Jian Xu1, Herbert Y Meltzer3, Anis Contractor4.   

Abstract

Repeated administration of non-competitive N-methyl-d-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) to rodents causes long-lasting deficits in cognition and memory, and has effects on behaviors that have been suggested to be models of the cognitive impairment associated with schizophrenia (CIAS). Despite this being a widely studied animal model, little is known about the long lasting changes in synapses and circuits that underlie the altered behaviors. Here we examined synaptic transmission ex-vivo in the hippocampus of mice after a subchronic PCP (scPCP) administration regime. We found that after at least one week of drug free washout period when mice have impaired cognitive function, the threshold for long-term potentiation (LTP) of CA1 excitatory synapses was elevated. This elevated LTP threshold was directly related to increased inhibitory input to CA1 pyramidal cells through increased activity of GABAergic neurons. These results suggest repeated PCP administration causes a long-lasting metaplastic change in the inhibitory circuits in the hippocampus that results in impaired LTP, and could contribute to the deficits in hippocampal-dependent memory in PCP-treated mice. Changes in GABA signaling have been described in patients with schizophrenia, therefore our results support using scPCP as a model of CIAS. This article is part of the Special Issue entitled 'Synaptopathy--from Biology to Therapy'.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GABA; Hippocampus; Inhibitory postsynaptic current; Long-term potentiation; Phencyclidine

Mesh:

Substances:

Year:  2015        PMID: 25937215      PMCID: PMC4584174          DOI: 10.1016/j.neuropharm.2015.04.012

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  46 in total

1.  Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia.

Authors:  G Keilhoff; A Becker; G Grecksch; G Wolf; H-G Bernstein
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

2.  Hippocampal-parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Jennifer Hadley; Meredith Amanda Reid; Adrienne Carol Lahti
Journal:  Hippocampus       Date:  2014-08-01       Impact factor: 3.899

3.  Neuropsychological function in schizophrenia. Selective impairment in memory and learning.

Authors:  A J Saykin; R C Gur; R E Gur; P D Mozley; L H Mozley; S M Resnick; D B Kester; P Stafiniak
Journal:  Arch Gen Psychiatry       Date:  1991-07

Review 4.  Alterations of cortical GABA neurons and network oscillations in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; Takanori Hashimoto; David A Lewis
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

5.  Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests.

Authors:  W Perry; G A Light; H Davis; D L Braff
Journal:  Schizophr Res       Date:  2000-12-15       Impact factor: 4.939

6.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

7.  Impaired GABAergic inhibition in the prefrontal cortex of early postnatal phencyclidine (PCP)-treated rats.

Authors:  Celia Kjaerby; Brian V Broberg; Uffe Kristiansen; Nils Ole Dalby
Journal:  Cereb Cortex       Date:  2013-04-23       Impact factor: 5.357

8.  Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat.

Authors:  Trisha A Jenkins; Michael K Harte; Claire E McKibben; Jennifer J Elliott; Gavin P Reynolds
Journal:  Behav Brain Res       Date:  2008-07-25       Impact factor: 3.332

Review 9.  Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models.

Authors:  Gavin P Reynolds; Zuhal Abdul-Monim; Joanna C Neill; Zhi-Jun Zhang
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice.

Authors:  Emily G Harlow; Sally M Till; Theron A Russell; Lasani S Wijetunge; Peter Kind; Anis Contractor
Journal:  Neuron       Date:  2010-02-11       Impact factor: 17.173

View more
  17 in total

Review 1.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

2.  Potentiating α2 subunit containing perisomatic GABAA receptors protects against seizures in a mouse model of Dravet syndrome.

Authors:  Toshihiro Nomura; Nicole A Hawkins; Jennifer A Kearney; Alfred L George; Anis Contractor
Journal:  J Physiol       Date:  2019-05-20       Impact factor: 5.182

3.  Contrasting Typical and Atypical Antipsychotic Drugs.

Authors:  Herbert Y Meltzer; Erick Gadaleta
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

4.  mGlu3 Metabotropic Glutamate Receptors-New Hope for Pharmacotherapy of Schizophrenia.

Authors:  Mariacristina Mazzitelli; Volker Neugebauer
Journal:  Biol Psychiatry       Date:  2021-09-15       Impact factor: 12.810

5.  GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.

Authors:  Lakshmi Rajagopal; Jeffrey S Burgdorf; Joseph R Moskal; Herbert Y Meltzer
Journal:  Behav Brain Res       Date:  2015-11-26       Impact factor: 3.332

6.  GABAergic inhibition gates excitatory LTP in perirhinal cortex.

Authors:  Vibhakar C Kotak; Ana Mirallave; Todd M Mowery; Dan H Sanes
Journal:  Hippocampus       Date:  2017-09-26       Impact factor: 3.899

7.  Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice.

Authors:  Lakshmi Rajagopal; Bill W Massey; Eric Michael; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2015-11-12       Impact factor: 4.530

8.  Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus.

Authors:  Shalini Dogra; Branden J Stansley; Zixiu Xiang; Weilun Qian; Rocco G Gogliotti; Ferdinando Nicoletti; Craig W Lindsley; Colleen M Niswender; Max E Joffe; P Jeffrey Conn
Journal:  Biol Psychiatry       Date:  2021-03-06       Impact factor: 12.810

9.  Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission.

Authors:  Alan L Pehrson; Christian S Pedersen; Kirstine Sloth Tølbøl; Connie Sanchez
Journal:  Front Pharmacol       Date:  2018-03-06       Impact factor: 5.810

10.  GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1.

Authors:  Dongsheng Zhou; Dan Lv; Zhen Wang; Yanhua Zhang; Zhongming Chen; Chuang Wang
Journal:  Front Mol Neurosci       Date:  2018-04-11       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.